Eli Lilly's stock is being closely watched, with some outlets suggesting it could still go higher. Morgan Stanley has reportedly expressed confidence in the company, particularly due to its product Mounjaro. The stock's future direction is uncertain, with some outlets discussing potential growth drivers and others highlighting potential catches or needing a rerating.